FDA issues warning letter to NeoGen over veterinary product quality defect
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
What happened
On October 7, 2026, the FDA issued a warning letter to NeoGen. This followed an investigation that linked the veterinary wound care product Neogen Vet HYCOAT, which was labeled sterile, to serious infections and deaths in horses. The FDA stated this incident involved at least 20 horse deaths.
From pr-inside.com
Why it matters
The FDA's action is part of enhanced U.S. food safety policies involving the FDA and NeoGen. The incident, which followed a voluntary recall of HYCOAT initiated by NeoGen in late January 2026, highlights regulatory risks associated with quality defects in veterinary medical products.
Enhanced U.S. food safety policies involve the FDA and NeoGen.
From pr-inside.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NeoGenSpeculative
NeoGen might face reduced sales or increased costs due to regulatory action regarding its product quality.
How it developed
Newest first. Tap a step to see who reported it.FDA investigated NeoGen's veterinary wound care product.1 source
FDA issued a warning letter to NeoGen over product quality defect.1 source
Keep exploring
The entities involved
Related events
- The FDA has issued a warning regarding a company due to quality lapses and is facing investigation over securities law violations.
- Beta Bionics, Inc. is accused of failing to accurately describe observations made by the FDA.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- The Food and Drug Administration (FDA) oversees product safety and recalls.
- BFA is investigating potential securities violations while the FDA issues a product safety warning to Once Upon a Farm, PBC.